In a multicenter single-arm phase I/II trial, Seto et al. aimed to assess the activity of alectinib in Japanese ALK-positive metastatic NSCLC patients, who had received no prior treatment with ALK-TKI. Here, ALK is linked to non-small cell lung carcinoma.